Every material Form 8-K Alpha Teknova, Inc. has filed with the SEC since August 05, 2026, read and summarized by AI: what happened, the key figures, whether it reads positive or negative for shareholders, and how big a deal it is (impact 1-5). Newest first; each brief links to its own page and to the filing on SEC.gov.
Alpha Teknova reported third-quarter 2026 revenue of $12.7 million, up 22% from a year earlier, and its net loss narrowed to $3.5 million from $4.3 million. The company raised its 2026 revenue guidance to $46 million to $48 million and closed a $46.0 million public offering of 9.2 million shares at $5.00 per share on October 22, 2026, which adds to the shares held by existing shareholders.
Q3 2026 revenue was $12.7 million, up 22% from $10.5 million; Clinical Solutions revenue rose 86% to $3.2 million.
Net loss was $3.5 million, or $0.06 per diluted share, versus $4.3 million, or $0.08 per share, in Q3 2025.
2026 revenue guidance raised to $46 million to $48 million; Free Cash Outflow guidance of less than $8 million was maintained.
Underwritten offering of 9.2 million shares at $5.00 closed October 22, 2026, with gross proceeds of $46.0 million and net proceeds of about $42.9 million.
On October 20, 2026, Alpha Teknova agreed to sell 8,000,000 common shares at $5.00 each, for expected gross proceeds of $40 million, and granted underwriters an option to buy 1,200,000 more shares. The company also disclosed preliminary third-quarter 2026 estimates showing revenue of $12.5 million to $12.7 million, an Adjusted EBITDA loss of $1.0 million to $1.2 million, and $16.6 million in cash and short-term investments, while noting the figures are unaudited and may change materially. The new shares will increase the number of shares outstanding for existing holders.
8,000,000 shares offered at $5.00; underwriters buy at $4.70 per share; closing expected on or about October 22, 2026
Proceeds are intended for general corporate purposes, potentially including repayment of outstanding debt; no current acquisition commitments
Preliminary Q3 2026 estimates: revenue $12.5 million to $12.7 million, gross margin 36.0% to 38.0%, net loss $3.5 million to $3.7 million
Directors and executive officers agreed to lock-up restrictions on share sales until January 19, 2027
Teknova reported second-quarter 2026 revenue of $12.2 million, up 18% from $10.3 million a year earlier, and its net loss narrowed to $3.2 million, or $0.06 per diluted share, from $3.6 million, or $0.07. The company raised its 2026 revenue guidance to $45 million to $47 million and now expects free cash outflow of less than $8 million for the year.
Q2 2026 revenue was $12.2 million, up 18% from $10.3 million; gross margin was 40.1% versus 38.7%.
Net loss was $3.2 million, or $0.06 per diluted share, compared with $3.6 million, or $0.07, in Q2 2025.
2026 revenue guidance raised to $45 million to $47 million; free cash outflow guidance is now less than $8 million.
Cash and short-term investments were $17.4 million and total borrowings were $13.2 million as of June 30, 2026.
Briefs are written by AI from the filing text and can contain mistakes — open the filing before acting on anything. Impact (1-5) and tone are the AI's reading of the filing for shareholders, not a price forecast. Not investment advice.
Only material 8-Ks get a brief: results, deals, executive changes, restructuring, impairments, delisting notices, restatements, cybersecurity incidents and other disclosed events. Routine filings (vote results, exhibits only) are skipped. Every Alpha Teknova, Inc. filing is on SEC EDGAR ↗. 8-K briefs of other companies →